Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies-Reference-Cited by-同舟云学术

Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies

Published:2019-03-19 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Lu Yingjuan J.,Chu Haiyan,Wheeler Leroy W.,Nelson Melissa,Westrick Elaine,Matthaei James F.,Cardle Ian I.,Johnson Adam,Gustafson Joshua,Parker Nikki,Vetzel Marilynn,Xu Le-Cun,Wang Emilia Z.,Jensen Michael C.,Klein Patrick J.,Low Philip S.,Leamon Christopher P.

Funder

Endocyte

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference53 articles.

1. Harnessing the immunotherapy revolution for the treatment of childhood cancers;Majzner;Cancer Cell.,2017

2. CAR T cell immunotherapy for human cancer;June;Science.,2018

3. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit “ALL”;Teachey;Nat Rev Clin Oncol.,2018

4. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy;Fry;Nat Med.,2018

5. Human Epidermal Growth Factor Receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma;Ahmed;J Clin Oncol.,2015

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances on immunotherapy for osteosarcoma;Molecular Cancer;2024-09-09

2. Current status and future challenges of CAR-T cell therapy for osteosarcoma;Frontiers in Immunology;2023-12-22

3. Imaging the Side Effects of CAR T Cell Therapy: A Primer for the Practicing Radiologist;Academic Radiology;2023-11

4. Control of the antitumour activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumour cells;Nature Biomedical Engineering;2023-10-05

5. Bringing cell therapy to tumors: considerations for optimal CAR binder design;Antibody Therapeutics;2023-09-12